Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms by Histologic Type 2Vascular Diseases 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pathologic Processes 1Paraproteinemias 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Lymphatic Diseases 1Lung Neoplasms 1Lung Diseases 1Liver Neoplasms 1Liver Diseases 1Lip Neoplasms 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × ficlatuzumab × Clear all
NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

University of Arizona

Phase 2 Completed
78 enrolled 16 charts
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡